Transdiaphragmatic Mucormycosis

Philipp Koehler; Robert Reimer; Roger Wahba; Birgid Schömig-Markiefka; Oliver A Cornely

doi:10.1093/cid/ciz533

Transdiaphragmatic Mucormycosis

Clin Infect Dis. 2020 Feb 14;70(5):940-942. doi: 10.1093/cid/ciz533.

Authors

Philipp Koehler^{1

2

3}, Robert Reimer⁴, Roger Wahba⁵, Birgid Schömig-Markiefka⁶, Oliver A Cornely^{1

2

3

7

8}

Affiliations

¹ Faculty of Medicine, Department I of Internal Medicine, University Hospital of Cologne, University of Cologne.
² Cologne Excellence Cluster on Cellular Stress Responses in Aging-associated Diseases (CECAD), University Hospital of Cologne, University of Cologne.
³ Faculty of Medicine, European Excellence Center for Medical Mycology (ECMM), University Hospital of Cologne, University of Cologne.
⁴ Department of Diagnostic and Interventional Radiology, University of Cologne, Germany.
⁵ Department of General, Visceral and Cancer Surgery, University of Cologne, Germany.
⁶ Institute of Pathology, University Hospital of Cologne, University of Cologne, Germany.
⁷ German Centre for Infection Research, Partner Site Bonn-Cologne, University of Cologne, Germany.
⁸ Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Germany.

PMID: 31222210
DOI: 10.1093/cid/ciz533

Abstract

Mucormycosis is a life-threatening infection. This is the first report of transdiaphragmatic mucormycosis in a series of 3 patients. We observed this phenomenon in 11% of patients. Clinicians should be aware of this possibly underreported entity, and as a consequence we envision more comprehensive imaging studies in patients with mucormycosis.

Keywords: isavuconazole; liposomal amphotericin B; posaconazole; radiology; zygomycosis.

MeSH terms

Antifungal Agents / therapeutic use
Humans
Mucormycosis* / diagnosis
Mucormycosis* / drug therapy
Triazoles

Substances

Antifungal Agents
Triazoles